Revvity, Inc. (RVTY) Earnings Call Transcripts
Revvity, Inc.'s Latest Earnings Call - September 15, 2026
In the Q2 2026 earnings call, Revvity, Inc. reported better-than-expected results, with revenue and earnings exceeding management's prior expectations. The company achieved revenue growth of 11% in its Diagnostics segment and maintained a strong backlog in Life Sciences, signaling potential for improved performance in the latter half of the fiscal year. Management raised guidance for Life Sciences instruments to mid-single digits for Q3 and Q4, reflecting a recovery in demand, particularly in high-content screening instruments. Overall, Revvity's focus on innovation and strategic acquisitions positions it well for future growth.
Reported metrics
| Metric | Value |
|---|---|
| Diagnostics Organic Growth | 11% (positive) |
| Life Sciences Instruments Growth Guidance | mid-single digits (positive) |
| High-Content Screening Backlog | null (positive) |
| China Life Sciences Revenue Contribution | 7% (positive) |
Guidance from management
Management raised guidance for Life Sciences instruments to mid-single digits for Q3 and Q4, reflecting improved demand expectations. They did not provide specific revenue guidance for the overall company.
What management said
Yes. Unfortunately, I'm not going to provide specifics on that. But I would say we have been seeing demand from both improvement in demand from both traditional as well as nontraditional customers. I would say the uptick or inflection in orders is probably more from traditional customers than it is from nontraditional customers, but the nontraditional customers, I think, is not insignificant and it's new. So I think ...
What analysts pressed on
Analysts expressed concerns regarding the lumpiness of software revenue recognition and its impact on organic growth. Additionally, there were questions about the sustainability of growth in the Diagnostics segment amid external pressures.
Main topics on the call
- Diagnostics Growth Acceleration — Revvity's Diagnostics segment saw organic growth accelerate from 9% in Q1 to 11% in Q2, driven by strong performance in reproductive health and immunodiagnostics. Management noted, "we're growing high single digits this ...
- Life Sciences Backlog Strength — The company reported the strongest backlog in 3-5 years, particularly in high-content screening instruments, which are expected to drive growth in the second half of the year. Management stated, "we exited the second qua...
- Guidance for Life Sciences Instruments — Management raised guidance for Life Sciences instruments from low single digits to mid-single digits for Q3 and Q4, indicating a recovery in demand. They expect this growth to be driven by high-content screening instrume...
- Software Revenue Recognition Challenges — Management highlighted the lumpiness in software revenue recognition due to GAAP accounting, impacting organic growth. They explained, "the way GAAP revenue recognition accounting works is it's very lumpy," which has cau...
Read the full Revvity, Inc. transcript (September 15, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Revvity, Inc.
Revvity, Inc. (RVTY) is a publicly listed company in the Life Sciences Tools and Services industry, within the Health Care sector. It trades on NYSE and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 93 calls on record spanning January 14, 2020 to September 15, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 93 Revvity, Inc. earnings call transcripts on record, spanning January 14, 2020 to September 15, 2026. Based on this history, Revvity, Inc. reports quarterly. The most recent call on file is dated September 15, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- RVTY
- Exchange
- NYSE
- Country
- US
- Sector
- Health Care
- Industry
- Life Sciences Tools and Services
- Calls on record
- 93
- First call
- January 14, 2020
- Most recent
- September 15, 2026
- Reporting cadence
- quarterly